Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: GSK1120212
Sponsor: UNC Lineberger Comprehensive Cancer Center
Collaborators: GlaxoSmithKline|National Cancer Institute (NCI)|Susan G. Komen Breast Cancer Foundation